Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2081667 | Drug Discovery Today | 2007 | 6 Pages |
Abstract
RNA interference (RNAi) and small-molecule approaches are synergistic on multiple levels, from technology and high-throughput screen development to target identification and functional studies. Here, we describe the RNAi screening platform that we have established and made available to the community through the Drosophila RNAi Screening Center at Harvard Medical School. We then illustrate how the combination of RNAi and small-molecule HTS can lead to effective identification of targets in drug discovery.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Norbert Perrimon, Adam Friedman, Bernard Mathey-Prevot, Ulrike S. Eggert,